Down Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?
The 7 major down syndrome markets reached a value of US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.8 Billion by 2034, exhibiting a growth rate (CAGR) of 10.91% during 2024-2034.
The down syndrome market has been comprehensively analyzed in IMARC’s new report titled “Down Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Down syndrome, also known as trisomy 21, is a genetic disorder caused by the presence of all or a portion of a third chromosome 21. It varies in severity among individuals, causing lifelong intellectual disability and developmental delays. Physical symptoms include a flattened face, poor muscle tone, external corners of the eyes which point upwards, inordinate flexibility, low-set ears, a short neck, as well as relatively short fingers and small hands and feet. The intellectual symptoms include varying degrees of cognitive impairment, usually accompanied by an interruption in language learning and both short and long-term memory being impacted. There are two timeframe-based approaches to diagnose down syndrome. First, when a woman is pregnant, the diagnosis can be made; however, confirmation requires further diagnostic tests. Another timeframe for identifying down syndrome is after childbirth. In this case, the condition is determined by assessing the child's external appearance and then examining their chromosomes.
The increasing incidences of chromosome-related genetic disorders coupled with the rising demand for novel therapeutics that can address the conditions effectively are primarily driving the down syndrome market. In addition to this, the escalating utilization of prenatal screenings, such as amniocentesis and chorionic villus sampling (CVS), for diagnosing the disorder is further creating a positive outlook for the market. Moreover, the widespread adoption of anticonvulsant drugs to treat the seizures associated with down syndrome is also propelling the market growth. Besides this, several key players are making significant investments to gain a better understanding of the down syndrome, thereby augmenting the global market. With early intervention, children and adults suffering from this disorder can significantly improve their quality of life. Furthermore, numerous NGOs and private organizations are offering support and information to families, educators, caregivers, employers, and professionals who serve individuals with down syndrome. This, in turn, is also positively influencing the global market. Additionally, the introduction of a wide range of physical and developmental therapies that are designed to help people with down syndrome reach their full potential is acting as a significant growth-inducing factor. Apart from this, several biotechnological advancements, such as the development of DNA-sequencing-based blood tests for enhanced screening accuracy, are further expected to drive the global down syndrome market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the down syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for down syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the down syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the down syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the down syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current down syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the down syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the down syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the down syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the down syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of down syndrome ?
What will be the growth rate of patients across the seven major markets?
Down Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for down syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the down syndrome market?
The down syndrome market has been comprehensively analyzed in IMARC’s new report titled “Down Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Down syndrome, also known as trisomy 21, is a genetic disorder caused by the presence of all or a portion of a third chromosome 21. It varies in severity among individuals, causing lifelong intellectual disability and developmental delays. Physical symptoms include a flattened face, poor muscle tone, external corners of the eyes which point upwards, inordinate flexibility, low-set ears, a short neck, as well as relatively short fingers and small hands and feet. The intellectual symptoms include varying degrees of cognitive impairment, usually accompanied by an interruption in language learning and both short and long-term memory being impacted. There are two timeframe-based approaches to diagnose down syndrome. First, when a woman is pregnant, the diagnosis can be made; however, confirmation requires further diagnostic tests. Another timeframe for identifying down syndrome is after childbirth. In this case, the condition is determined by assessing the child's external appearance and then examining their chromosomes.
The increasing incidences of chromosome-related genetic disorders coupled with the rising demand for novel therapeutics that can address the conditions effectively are primarily driving the down syndrome market. In addition to this, the escalating utilization of prenatal screenings, such as amniocentesis and chorionic villus sampling (CVS), for diagnosing the disorder is further creating a positive outlook for the market. Moreover, the widespread adoption of anticonvulsant drugs to treat the seizures associated with down syndrome is also propelling the market growth. Besides this, several key players are making significant investments to gain a better understanding of the down syndrome, thereby augmenting the global market. With early intervention, children and adults suffering from this disorder can significantly improve their quality of life. Furthermore, numerous NGOs and private organizations are offering support and information to families, educators, caregivers, employers, and professionals who serve individuals with down syndrome. This, in turn, is also positively influencing the global market. Additionally, the introduction of a wide range of physical and developmental therapies that are designed to help people with down syndrome reach their full potential is acting as a significant growth-inducing factor. Apart from this, several biotechnological advancements, such as the development of DNA-sequencing-based blood tests for enhanced screening accuracy, are further expected to drive the global down syndrome market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the down syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for down syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the down syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the down syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the down syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current down syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the down syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the down syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the down syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the down syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of down syndrome ?
What will be the growth rate of patients across the seven major markets?
Down Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for down syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the down syndrome market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DOWN SYNDROME - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.3 Market Overview (2018-2023) and Forecast (2024-2034?)
4.4 Competitive Intelligence
5 DOWN SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DOWN SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
8 DOWN SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DOWN SYNDROME - UNMET NEEDS
10 DOWN SYNDROME - KEY ENDPOINTS OF TREATMENT
11 DOWN SYNDROME - MARKETED PRODUCTS
11.1 List of Down Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 DOWN SYNDROME - PIPELINE DRUGS
12.1 List of Down Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Donepezil - Eisai
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ACI 24 - AC Immune
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Buntanetap - Annovis Bio
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. DOWN SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 DOWN SYNDROME - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Down Syndrome - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034?)
14.2.2 Down Syndrome - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034?)
14.3 Market Scenario - United States
14.3.1 Down Syndrome - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034?)
14.3.2 Down Syndrome - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034?)
14.3.3 Down Syndrome - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Down Syndrome - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034?)
14.4.2 Down Syndrome - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034?)
14.4.3 Down Syndrome - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Down Syndrome - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034?)
14.5.2 Down Syndrome - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034?)
14.5.3 Down Syndrome - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Down Syndrome - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034?)
14.6.2 Down Syndrome - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034?)
14.6.3 Down Syndrome - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Down Syndrome - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034?)
14.7.2 Down Syndrome - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034?)
14.7.3 Down Syndrome - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Down Syndrome - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034?)
14.8.2 Down Syndrome - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034?)
14.8.3 Down Syndrome - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Down Syndrome - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034?)
14.9.2 Down Syndrome - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034?)
14.9.3 Down Syndrome - Access and Reimbursement Overview
15 DOWN SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 DOWN SYNDROME MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DOWN SYNDROME - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.3 Market Overview (2018-2023) and Forecast (2024-2034?)
4.4 Competitive Intelligence
5 DOWN SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DOWN SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
8 DOWN SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DOWN SYNDROME - UNMET NEEDS
10 DOWN SYNDROME - KEY ENDPOINTS OF TREATMENT
11 DOWN SYNDROME - MARKETED PRODUCTS
11.1 List of Down Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 DOWN SYNDROME - PIPELINE DRUGS
12.1 List of Down Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Donepezil - Eisai
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ACI 24 - AC Immune
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Buntanetap - Annovis Bio
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. DOWN SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 DOWN SYNDROME - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Down Syndrome - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034?)
14.2.2 Down Syndrome - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034?)
14.3 Market Scenario - United States
14.3.1 Down Syndrome - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034?)
14.3.2 Down Syndrome - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034?)
14.3.3 Down Syndrome - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Down Syndrome - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034?)
14.4.2 Down Syndrome - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034?)
14.4.3 Down Syndrome - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Down Syndrome - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034?)
14.5.2 Down Syndrome - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034?)
14.5.3 Down Syndrome - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Down Syndrome - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034?)
14.6.2 Down Syndrome - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034?)
14.6.3 Down Syndrome - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Down Syndrome - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034?)
14.7.2 Down Syndrome - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034?)
14.7.3 Down Syndrome - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Down Syndrome - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034?)
14.8.2 Down Syndrome - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034?)
14.8.3 Down Syndrome - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Down Syndrome - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034?)
14.9.2 Down Syndrome - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034?)
14.9.3 Down Syndrome - Access and Reimbursement Overview
15 DOWN SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 DOWN SYNDROME MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
